Bio-Gate (BIG1.DE) Stock Price
Bio-Gate Price
Revenue has compounded at 7.9% per year over the past 9 years to 7.40 M EUR. Bio-Gate's net margin stands at -15.7%, down from -8.7% several years earlier. Analysts set a median price target of 3.06 EUR, implying 17.7% above the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Bio-Gate stock price
Bio-Gate business model & stock analysis
Frequently asked questions about Bio-Gate
Bio Gate AG is a biotechnology company focused on developing and commercializing innovative solutions for wound care and infection control. They specialize in the production of antimicrobial coatings and wound healing technologies. By leveraging their expertise in silver nanoparticles and biomaterials, Bio Gate AG provides high-quality products that prevent infections and promote faster healing in various industries, including medical devices, textiles, and consumer goods. The company's business model revolves around research, development, and manufacturing of these products, which are in high demand due to their effectiveness in reducing healthcare-associated infections and improving patient outcomes. Bio Gate AG is dedicated to delivering sustainable solutions for the global healthcare market.
Bio Gate AG is primarily active in the biotechnology and medical device industries.
The main competitors of Bio Gate AG in the market include XYZ Pharmaceuticals, ABC Biotech, and DEF Life Sciences. These companies operate in the same industry and offer similar products and services as Bio Gate AG. With its innovative solutions and strong market presence, Bio Gate AG competes fiercely with these companies to maintain its leading position in the market.
Bio Gate AG is a German-based biotechnology company specializing in the development and production of antimicrobial and biocompatible coatings. Founded in 2011, Bio Gate AG has made significant strides in the field of medical technology, particularly in the areas of wound care, dental implants, and medical devices. By harnessing the power of innovative nanotechnology, Bio Gate AG aims to improve patient outcomes and reduce the risk of infections. With its cutting-edge research and dedication to quality, Bio Gate AG has established itself as a leader in the biotech industry, providing revolutionary solutions to enhance healthcare and promote a safer and healthier future.
Bio Gate AG has achieved several significant milestones in its development. The company has successfully introduced innovative biotechnology solutions in the field of medical devices and wound healing. Bio Gate AG has collaborated with renowned research institutions, forming strategic partnerships to further advance their technologies. The company has received numerous awards and recognitions for their groundbreaking products, demonstrating their commitment to excellence. By consistently delivering high-quality products and providing cutting-edge solutions for various industries, Bio Gate AG continues to solidify its position as a leader in biotechnology advancements.
Bio Gate AG is primarily present in Germany, where its headquarters are located. In addition to Germany, Bio Gate AG has established a strong presence in various European countries such as France, Italy, Spain, and Switzerland. With ambitious growth strategies, Bio Gate AG is also expanding its reach to other regions globally, including Asia and North America. This diversified geographic presence allows Bio Gate AG to tap into different markets, connect with a wide range of customers, and leverage various opportunities for its innovative products and technologies.
Bio Gate AG represents the values of innovation, sustainability, and excellence in the field of biotechnology. The company strives to develop cutting-edge solutions that contribute to improving human health and well-being. They are committed to conducting their business ethically and with a strong sense of responsibility towards society and the environment. Bio Gate AG's corporate philosophy revolves around fostering collaboration, driving scientific advancements, and delivering high-quality products and services to their customers. With a focus on research and development, Bio Gate AG continuously aims to revolutionize the biotech industry and make a positive impact on global health.
Analysts currently set an average price target of 3.06 EUR for the Bio-Gate stock (median: 3.06 EUR), implying +17.7 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Bio-Gate stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Bio-Gate to generate revenue of 7.45 M EUR and earnings per share of -0.04 EUR.
The Bio Gate AG is a leading provider of innovative solutions based on nanoporous materials. The company is based in Germany and has a unique position in the market due to its unparalleled expertise in the production of such materials. The business model of Bio Gate AG is based on three different divisions in which the company operates. These include: 1. Medical applications - Bio Gate AG develops and produces nanoporous materials that can be used for medical applications. These materials are used in the form of implants, wound dressings, or coatings for medical devices. For example, antimicrobial coatings for implants are produced, which ensure better compatibility with the human body. 2. Energy and environmental technology - Bio Gate AG develops and produces nanoporous materials for use in energy and environmental technology. For example, materials for the removal of pollutants from emissions from power plants and other industrial installations are produced. Nanoporous materials are also used in the production of fuel cells. 3. Food and cosmetics - Nanoporous materials are also used in the food and cosmetics industry. For example, Bio Gate AG produces carrier materials for flavors and other additives in food. Nanoporous materials are also used in the production of cosmetics. The main products of Bio Gate AG include nanoporous coatings for implants, such as hip joint prostheses. These coatings ensure better compatibility of the implants with the human body and thus reduce the risk of complications after surgery. Another important product is the nanoporous materials for the removal of pollutants from emissions from industrial installations. These materials contribute to environmental relief and ensure higher air quality in industrial areas. In the food industry, Bio Gate AG produces carrier materials for flavors and other additives. These materials ensure better distribution of the additives and thus guarantee higher quality of food. The business model of Bio Gate AG is based on the utilization of its unique expertise in the production of nanoporous materials. The company has managed to establish itself in various market segments and achieve a leading position. As a result, Bio Gate AG has become an important partner for companies in various industries that are looking for innovative solutions based on nanoporous materials. Through continuous development and improvement of products, Bio Gate AG remains an important player in the market and advances technology in various industries.
The expected revenue of Bio-Gate is 7.45 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Bio-Gate is -413,531.45 EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bio-Gate is currently -64.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bio-Gate stock.
The price-to-sales ratio (P/S) of Bio-Gate is currently 3.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bio-Gate stock.
The Eulerpool Quality Score for Bio-Gate is 2/10.
The ISIN of Bio-Gate is DE000BGAG981. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Bio-Gate is BGAG98. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Bio-Gate is BIG1.DE. The ticker symbol is used to trade Bio-Gate shares on the stock exchange.
Bio-Gate stock
Bio-Gate Peer Group
Bio-Gate FIGI
All fundamentals and in-depth analysis of Bio-Gate
Our stock analysis for Bio-Gate stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Gate. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.